Cover Image
Market Research Report

Global Stem Cell Technologies and Applications Market 2020-2030: By Applications (Therapeutics [Cancer, Cardiovascular, CNS, Other], Non-Therapeutics), by Region (North America, Europe, Asia Pacific, ROW), Company Profiling

Published by Visiongain Ltd Product code 935845
Published Content info 311 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Stem Cell Technologies and Applications Market 2020-2030: By Applications (Therapeutics [Cancer, Cardiovascular, CNS, Other], Non-Therapeutics), by Region (North America, Europe, Asia Pacific, ROW), Company Profiling
Published: March 24, 2020 Content info: 311 Pages
Description

The global stem cell technologies and applications market is estimated to have reached US $17,791.8 million 2020 and is expected to grow at a CAGR of 11.8% in the first half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 311-page report you will receive 165 charts- all unavailable elsewhere.

The 311-page report provides clear detailed insight into the global stem cell technologies and applications market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope:

Global Stem Cell Technologies and Applications Market forecasts from 2020-2030

Global Stem Cell Technologies and Applications submarket forecasts from 2020-2030:

  • Cancer treatment
  • Cardiovascular therapy
  • CNS
  • Other therapies
  • Non-therapeutic applications

Individual revenue forecast to 2030 for selected top products:

  • MSC-100-IV (Mesoblast)
  • Hearticellgram-AMI (Pharmicell)
  • CardioRel (Reliance Life Sciences)
  • Osteocel Plus (NuVasive)
  • Trinity Evolution and Elite (Orthofix)
  • CARTISTEM (MEDIPOST)

Analysis of the most promising pipeline therapies in each therapeutic segment

Discussion on regulatory environments and developments in the US, Japan, Europe and other leading countries

Analysis of what drives and restrains the market

This study also discusses other influences on that field, including these:

  • Haematopoietic stem cell transplantation (HSCT)
  • Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
  • Uses for umbilical cord blood and related technologies, including cellular and blood banking
  • Agents for osteogenesis and treating autoimmune conditions
  • Applications in cell-based assays, diagnostics and drug development.

Key questions answered by this report:

  • What is the size of the total stem cells market, and how will the market evolve between 2020 and 2030?
  • How will the main segments within the overall stem cells market develop between 2020-2030?
  • What are the main drivers and restraints that will shape the overall stem cells market, and its individual segments over the next ten years?
  • What is the state of stem cell research in the different therapeutic segments?
  • What are some of the most prominent companies within this space, and what are their latest developments?
  • What are the most promising pipeline therapies in each therapeutic segment?
  • What are the revenue prospects for some of the stem cell therapies which have already been approved?
  • What are the main strengths, weaknesses, opportunities and threats for the stem cell market?
  • What are the main social, technological, economic and political factors that influence this market?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Stem Cell Technologies and Applications Market. You find data, trends and predictions.

Buy our report today Global Stem Cell Technologies and Applications Market 2020-2030: By Applications (Therapeutics (Cancer, Cardiovascular, CNS, Other Disease Areas), Non-Therapeutics), by Region (North America, Europe, Asia Pacific, Rest of the World) and Company Profiling.

Visiongain is a trading partner with the US Federal Government.

Table of Contents
Product Code: PHA0731

Table of Contents

1. Report Overview

  • 1.1 Global Stem Cell Technologies and Applications Market Overview
  • 1.2 Why you should Read This Report
  • 1.3 How this Report Delivers
  • 1.4 Key Questions Answered by This Report
  • 1.5 Who is this Report for?
  • 1.6 Research and Analysis Methods
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to Stem Cell Technologies and Applications

  • 2.1 What are Stem Cells? Defining Characteristics
  • 2.2 Timeline of Stem Cell Research
  • 2.3 Embryonic Stem Cells (ESCs) Enter the Picture
  • 2.4 Classifying Stem Cells by Potency
    • 2.4.1 Post Fertilisation and Germ Layers
  • 2.5 The Main Types of Stem Cells and Their Properties
  • 2.6 iPSCs: The Benefits of ESCs, but Without the Downsides?
    • 2.6.1 CIRM hPSC Repository Launches 300 iPSC Lines
  • 2.7 Parthenogenetic Stem Cells: Scientific Background
    • 2.7.1 Are they Ethical Alternatives to ESCs? What are the Commercial Applications?
  • 2.8 Autologous Versus Allogeneic Stem Cells
    • 2.8.1 Are Universal Stem Cell Products Possible?
  • 2.9 Phases of Clinical Trials
  • 2.10 Scope of this Report

3. International Developments and Stem Cell Regulatory Environments

  • 3.1 Regulatory Environment in the US
    • 3.1.1 Dynamic Biotechnology Sector and Liberal Stance on Patents
    • 3.1.2 Understanding 'Homologous' Use
    • 3.1.3 Controversy Surrounding ESC Research
    • 3.1.4 NIH ESC Stem Cell Registry: Has Made Good Progress, but not enough for its Critics
    • 3.1.5 CIRM and NIH Stem Cell Funding into Various Channels
    • 3.1.6 FDA vs Regenerative Sciences
    • 3.1.7 Are Stem Cells Clinics the 'Wild West' of Medicine?
    • 3.1.8 Stem Cell Clinics Using Loopholes to Avoid Oversight?
    • 3.1.9 FDA Releases Three New Draft Guidances, but is it Doing Enough?
  • 3.2 Regulatory Environment in Europe
    • 3.2.1 Unified Overarching System of Regulation Across EU
    • 3.2.2 Difference between EU Member States Regarding hESC Research
    • 3.2.3 European Court of Justice Performs a U-Turn and Clears Path towards Stem Cell Patents
    • 3.2.4 The UK: A Leader in European Stem Cell Research
  • 3.3 Regulatory Environment in Japan
    • 3.3.1 Liberal Stance on hESC but with Excessive Bureaucracy?
    • 3.3.2 Japan: A Pioneer in iPSC Research, Although First In-Human Trial has been suspended
    • 3.3.3 The STAP Cell Events: Excitement Dashed
      • 3.3.3.1 Riken Concludes Investigation
    • 3.3.4 Government Committed to Regenerative Medicines and iPSC Research
    • 3.3.5 Japan Becomes Very Attractive Market for Stem Cell Companies due to Favourable Regulatory Changes
  • 3.4 Regulatory Environment in South Korea
    • 3.4.1 Highs and Lows with Regard to hESC Research in South Korea
    • 3.4.2 Regulators are Quick to Approve Therapies, although this has Drawn Criticism
    • 3.4.3 Tracheal Transplant Patient Dies
    • 3.4.4 New changes a requirement for the current research and development in HESC
  • 3.5 Chinese Regulatory Environment
    • 3.5.1 Liberal Regulation on Stem Cells and Very High Number of Stem Cell Clinical Trials Taking Place in the Country
    • 3.5.2 Stem Cell Medical Tourism Very Popular
    • 3.5.3 CFDA Releases New Stem Cell Draft Guidance
  • 3.6 Israel Regulatory Environment: A Strong Presence in Stem Cell Research
  • 3.7 Indian Regulatory Environment: Emerging Stem Cell Industry - in Need of more Regulation?

4. Stem Cell Technologies and Applications: World Market 2019-2030

  • 4.1 Therapeutic Applications versus Non-Therapeutic Applications of Stem Cells
  • 4.2 Regional Breakdown of the World Market
  • 4.3 Market Segmentation
  • 4.4 Stem Cell Technologies and Applications Market: Forecast 2019-2030
  • 4.5 Stem Cell Technologies and Applications Market: Forecast, by Segment, 2019-2030
  • 4.6 How Will Segmental Market Shares Change by 2030?
  • 4.7 Stem Cell Technologies and Applications Market: Drivers and Restraints

5. Stem Cell Cancer Therapeutics Segment 2019-2030

  • 5.1 Stem Cell Cancer Therapeutics: Overview and Current Status
  • 5.2 Stem Cell Cancer Therapeutics: Market Forecast 2019-2030
  • 5.3 Haematopoietic Stem Cell Transplantation (HCST)
    • 5.3.1 An Established Treatment for Haematological Cancers
    • 5.3.2 Autologous HSCT: Dominant Form of HSCT
    • 5.3.3 Autologous Versus Allogeneic HSCT: Advantages and Disadvantages
    • 5.3.4 GvHD: The Major Issue for HSCT
    • 5.3.5 Strengths and Weaknesses of the Three Major Sources of HSCs
    • 5.3.6 What is Cord Blood?
    • 5.3.7 Number of HSCT Operations Performed Worldwide, Split by Autologous Versus Allogeneic HSCT, 2015-2017
      • 5.3.7.1 Numbers of HSCT Operations Performed in Europe, Split by Donor Type, 2011-2017
    • 5.3.8 HSCT Costs and Medicare Coverage
    • 5.3.9 The Indications which can be treated with HSCT: Haematological Malignancies are the Major Indications
    • 5.3.10 HSCT has the Potential to Address Multiple Cancers, which represent a $20bn+ Market
  • 5.4 From Procedures to Products: Cord Blood Stem Cell Approvals
    • 5.4.1 Hemacord (New York Blood Center): The First FDA-Approved Cord Blood Product
      • 5.4.1.1 Hemacord Awarded Prix Galien 'Best Biotechnology Product' Award
    • 5.4.2 HPC, Cord Blood (ClinImmune Labs / University of Colorado Blood Bank)
    • 5.4.3 Ducord (Duke University School of Medicine)
    • 5.4.4 Allocord (SSM Cardinal Glennon Children's Medical Center)
    • 5.4.5 HPC, Cord Blood BLA 125432 (LifeSouth Community Blood Centers)
    • 5.4.6 CLEVECORD
    • 5.4.7 HPC, Cord Blood (BLA 125585)
  • 5.5 Stem Cell Cancer Therapeutics Pipeline
    • 5.5.1 Agenmestencel-T (Apceth)
    • 5.5.2 CLT-008 and CLT-009 (Cellerant Therapeutics): Company Receives $47.5m Grant from the US Government
    • 5.5.3 ProHema (Fate Therapeutics)
      • 5.5.3.1 ProTmune
    • 5.5.4 StemEx and NiCord (Gamida Cell)
      • 5.5.4.1 StemEx Shows Improved Survival at 100 Days - but FDA Wants Another Clinical Trial
      • 5.5.4.2 Copper Chelator Based Technology
      • 5.5.4.3 NiCord
      • 5.5.4.4 NiCord: The Company Aiming for a “Paradigm Shift” in Treatment Practice, Receives Orphan Drug Designation
      • 5.5.4.5 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
      • 5.5.4.6 NAM Technology Platform
      • 5.5.4.7 Novartis Chooses not to buy Gamida Cell
    • 5.5.5 MSC-100-IV (Previously Known as Prochymal) and Unnamed MPC-Expanded Cord Blood Product (Mesoblast)
      • 5.5.5.1 MSC-100-IV: World's First Approved Stem Cell Drug Outside of South Korea
      • 5.5.5.2 MSC-100-IV: Culture Expanded and Able to Treat GvHD
      • 5.5.5.3 An Important Role to Play in the Future of HSCT
      • 5.5.5.4 Wins Approval in Japan, through Partner JCR Pharmaceuticals, and Phase III Trial will Support US BLA
      • 5.5.5.5 MSC-100-IV / Temcell HS Injection Revenue Forecast 2019-2030
      • 5.5.5.6 MPC-Expanded Cord Blood Product in a Phase III Trial for Haematological Malignancies
    • 5.5.6 HSC835 (Novartis)
      • 5.5.6.1 Novartis Enters Partnership Agreement with Regenerex to Develop Novel Cell-Based Therapies
      • 5.5.6.2 Collaborations with Intellia Therapeutics and Caribou for CRISPR and HSCs
      • 5.5.6.3 Collaborations with Gamida Cell, Israel
    • 5.5.7 Ancillary Products for the HSCT Setting
    • 5.5.8 Targeting of Cancer Stem Cells (CSCs)
  • 5.6 Stem Cell Cancer Therapeutics: Drivers and Restraints 2019-2030

6. Stem Cell Cardiovascular Therapeutics Market Segment, 2019-2030

  • 6.1 Stem Cell Cardiovascular Therapeutics: Overview and Current Status
  • 6.2 Stem Cell Cardiovascular Therapeutics: Market Forecast 2019-2030
  • 6.3 Cardiovascular Diseases Make up a Large part of the Global Pharmaceuticals Market
    • 6.3.1 Stem Cell Treatments for Stroke: Touched Upon in This Chapter but mainly Covered under Central Nervous System Therapeutics
  • 6.4 Stem Cell Cardiovascular Therapeutics on the Market
    • 6.4.1 Hearticellgram-AMI (Pharmicell)
      • 6.4.1.1 One of the First Approved Cardiovascular Stem Cell Treatments Globally
      • 6.4.1.2 Hearticellgram-AMI Sales Estimates 2014-2017
      • 6.4.1.4 Hearticellgram-AMI Revenue Forecast 2019-2030
    • 6.4.2 CardioRel (Reliance Life Sciences)
      • 6.4.2.1 Available in the Indian Market, but does Data Back it up?
      • 6.4.2.2 CardioRel Revenue Forecast 2019-2030
    • 6.4.3 Cardiovascular and Cerebrovascular Conditions are the World's Most Fatal Diseases
    • 6.4.4 AMI, CLI and Stroke: Major Ischemic Disease Targets
  • 6.5 The State of Stem Cell Research for Cardiovascular Diseases
    • 6.5.1 Practical Advantages to Choosing the Heart as a Target for Stem Cell R&D
    • 6.5.2 Defining Cardiovascular Stem Cells: Scientific Context
  • 6.6 The Mysterious Effects of Stem Cells in the Heart
    • 6.6.1 MSCs in the Heart: Evidence to Support their Use, as well as Doubts over their Efficacy
    • 6.6.2 Cardiosphere-Derived Cells, hESC-Derived Cardiomyocytes and C-kit Cells
  • 6.7 Stem Cell Cardiovascular Therapeutics Pipeline
    • 6.7.1 Ixmyelocel-T (Vericel Corporation)
      • 6.7.1.1 Vericel Shifts Focus Away from CLI and Towards DCM
      • 6.7.1.2 Currently it has obtained RMAT designation
    • 6.7.2 Alecmestencel-T (Apceth)
    • 6.7.3 Arteriocyte: Using its 'Magellan System' to Treat CLI
    • 6.7.4 MultiStem (Athersys) for Myocardial Infarction and Stroke
      • 6.7.4.1 Updates from Athersys Regarding Trial Status
    • 6.7.5 Baxter: Phase 3 CD34+ Stem Cell Therapy for Refractory Angina
    • 6.7.6 CardiAMP (BioCardia) for Heart Failure: Scheduled to Finally Begin Phase 3 in January 2017
    • 6.7.7 MyoCell (U.S. Stem Cell, Inc. - Formerly Bioheart): Autologous 'Muscle Stem Cell' Therapy
      • 6.7.7.1 MyoCell: Is the Company Still Trying to Secure Funds to Restart the Phase II/III MARVEL Trial?
      • 6.7.7.2 MyoCell: MIRROR Trial on Hold
      • 6.7.7.3 MyoCell SDF-1: Improved Version of MyoCell
      • 6.7.7.4 MyoCell SDF-1 Phase 1 Trial (Regen): Another Trial Put on Hold
    • 6.7.8 CAP-1001 and CAP-1002 (Carpricor): Cardiospehere-Derived Cells for Heart Repair
    • 6.7.9 Ceylad (Formerly Cardio3): Proprietary Cardiopoiesis Technology Platform - Can be Applied to Various Stem Cell Sources
      • 6.7.9.1 C-Cure: Stem Cell Therapy for the Treatment of Heart Failure
      • 6.7.9.2 C-Cure: Two Phase III Trials Under Way
    • 6.7.10 Mesoblast: Mesenchymal Precursor Cells for Heart Failure and Myocardial Infarction
      • 6.7.10.1 Rexlemestrocel-L for Congestive Heart Failure (CHF), Chief Executive Provides Update
      • 6.7.10.2 CEP-41750: Promising Phase II Results, More Effective in a Particular Subset of Heart Failure Patients?
      • 6.7.10.3 Phase II Trial of MPCs in Acute Myocardial Infarction
    • 6.7.11 Caladrius Biosciences: Will not Continue Development of CLBS10, the Company's Former Lead Candidate
      • 6.7.11.1 CLBS12 for CLI: Due to Start Phase II in Japan in January 2016
    • 6.7.12 Stemedica Cell Technologies: 'Ischaemic-Tolerant' Stem Cell Platform
      • 6.7.12.1 Trials in Myocardial Infarction and Stroke
    • 6.7.13 Gemacell and Cryocell (Human Stem Cells Institute): Awaiting Important Russian Legislation to be Passed before Development Can Continue
  • 6.8 Stem Cell Cardiovascular Therapeutics: Drivers and Restraints, 2019-2030

7. Stem Cell Central Nervous System Therapeutics Segment, 2019-2030

  • 7.1 Stem Cell Central Nervous System Therapeutics: Overview and Current Status
  • 7.2 Stem Cell Central Nervous System Therapeutics: Market Forecast 2019-2030
  • 7.3 The State of Stem Cell Research in CNS Diseases
    • 7.3.1 Stem Cells are the Best Hope for Many Serious CNS Conditions
    • 7.3.2 Awaiting a First Breakthrough Approval
    • 7.3.3 Human Neural Stem Cells (NSCs) Successfully Isolated
    • 7.3.4 NSCs Reach the Clinic without Serious Controversy
    • 7.3.5 CNS Disorders are a Major Focus for ESC Research
    • 7.3.6 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
  • 7.4 Progress in Specific CNS Conditions
    • 7.4.1 HSCT in MS: Could 'Resetting' the Immune System Treat MS?
      • 7.4.1.1 Clinical Trials Involving HSCT in MS
      • 7.4.1.2 Barriers to Overcome before HSCT could become an Established Therapy for MS
    • 7.4.2 ALS: Could this Rare Disease be the First Neurodegenerative Condition for Stem Cell Treatment?
    • 7.4.3 Parkinson's Disease: Field Recovering after Voluntary Moratorium on Stem Cell Research by Many Western Nations Ends
    • 7.4.4 Dry Age-Related Macular Degeneration: A Major Unmet Need
  • 7.5 Several Multi-Billion Dollar Markets are Open to Stem Cell Developers if they can Translate the Potential of Stem Cells into Therapies
  • 7.6 Stem Cell Central Nervous System Therapeutics Pipeline
    • 7.6.1 MA09-hRPE (Ocata Therapeutics): Stem Cells for Eye Diseases
      • 7.6.1.1 Orphan Drug Status in both the US and EU
      • 7.6.1.2 Current Clinical Trials in SMD
      • 7.6.1.3 Early Signs of Efficacy
      • 7.6.1.4 Has Moved into Phase II in AMD
    • 7.6.2 NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor -Releasing Stem Cells for ALS
      • 7.6.2.1 Phase II Trial in 48 ALS Patients Underway
      • 7.6.2.2 Phase IIa Results Demonstrate “Statistically Significant Effect”
    • 7.6.3 International Stem Cell Corporation: Company Signals Intent to Start Phase I/IIa Study in PD Soon
    • 7.6.4 Neuralstem: Allogeneic NSCs for Synaptic Repair and Neuroprotection
      • 7.6.4.1 NSI-566 in ALS
      • 7.6.4.2 NSI-566 in ALS: Encouraging Data from Completed Phase 2 Trial
      • 7.6.4.3 NSI-566 for Chronic Spinal Cord Injury: Phase I Top-Line Data Expected Q4 2015
      • 7.6.4.4 NSI-566 for Ischaemic Stroke: Phase I/II Trials Underway in China
      • 7.6.4.5 Preclinical Investigation in 11 Other Indications
    • 7.6.5 PF-05206388 (Pfizer and the London Project to Cure Blindness): Finally Begins Phase I Trial, with first Successful Surgery
    • 7.6.6 Q-Cells (Q Therapeutics): Phase 1/2 Trial Begins
    • 7.6.7 ReNeuron: CTX Neural Cell Line and its Advantages
      • 7.6.7.1 CTX for Stroke
      • 7.6.7.2 CTX for Stroke: Long-Term PISCES Study Shows Promising Results
      • 7.6.7.3 CTX for Stroke: Undergoing Phase II, Using Highest Cell Dose from PISCES Study
    • 7.6.8 SB623 (SanBio): Enters Phase II for Stroke, as well as for Traumatic Brain Injury
    • 7.6.9 StemCells, Inc: A Leader in Neural Stem Cells
      • 7.6.9.1 HuCNS-SC for Pelizaeus-Merzbacher Disease: Undergoing Second Phase I Trial
      • 7.6.9.2 HuCNS-SC for NCL: Second Phase I Trial Withdrawn
      • 7.6.9.3 HuCNS-SC for Spinal Cord Injury: Phase II
      • 7.6.9.4 HuCNS-SC for AMD: Top-Line Phase I/II Results Released
  • 7.7 Stem Cell Central Nervous System Therapeutics: Drivers and Restraints 2019-2030

8. Stem Cell Therapeutics in Other Disease Areas 2019-2030

  • 8.1 Stem Cell Therapeutics in Other Disease Areas: Overview and Current Status
  • 8.2 Stem Cell Therapeutics in Other Disease Areas: Market Forecast 2019-2030
  • 8.3 Stem Cell Therapeutics in Other Disease Areas: Therapies on the Market
    • 8.3.1 Osteocel Plus (NuVasive)
      • 8.3.1.1 Osteocel to Osteocel Plus: Passing Through Different Companies and Patent Disputes
      • 8.3.1.2 The Leading Stem Cell Orthobiologic
      • 8.3.1.3 Is it Better than Autograft?
      • 8.3.1.4 Osteocel Plus Revenue Forecast 2019-2030
    • 8.3.2 Trinity Evolution and Trinity Elite (Orthofix): Stem Cell Orthobiologics
      • 8.3.2.1 Positive Results from New Trial in Foot and Ankle Procedures
      • 8.3.2.2 Trinity Evolution and Elite Revenue 2010-2014
      • 8.3.2.3 Trinity Evolution and Elite Revenue Forecast 2019-2030
    • 8.3.3 CARTISTEM (MEDIPOST)
      • 8.3.3.1 CARTISTEM: The World's First Allogeneic Stem Cell Drug
      • 8.3.3.2 CARTISTEM: Latest Updates Includes Results from Phase III Trial, Initiation of Phase I/II Trial in the US
      • 8.3.3.3 CARTISTEM: Revenues 2014 -2016
      • 8.3.3.4 CARTISTEM Revenue Forecast 2019-2030
    • 8.3.4 Allostem (Allosource)
    • 8.3.5 Map3 (RTI Surgical)
    • 8.3.6 ReliNethra for Ocular Surface Damage (Reliance Life Sciences)
    • 8.3.7 Cupistem (Anterogen)
  • 8.4 Stem Cell Therapeutics for Other Diseases: Research Areas
    • 8.4.1 HSCT for Orphan Diseases
    • 8.4.2 Potential for Genetically Modified Stem Cells for HIV and Other Diseases?
    • 8.4.3 Stem Cells Contribute to the Osteogenesis Process in Bone Repair
    • 8.4.4 Stem Cells Gaining Increasing Importance in Bone Graft Market, but whether these are True 'Stem Cell Products' is Debatable
    • 8.4.5 Stem Cells also have Potential in Autoimmune Disorders
    • 8.4.6 Potential Cure for Diabetes?
      • 8.4.6.1 Clinical Stage Programmes in Diabetes
    • 8.4.7 Stem Cells in Active Liver Repair
    • 8.4.8 Long-Term Possibilities
  • 8.5 Stem Cell Therapeutics in Other Disease Areas: Pipeline
    • 8.5.1 ALLO-ASC and ALLO-ASC-DFU (Anterogen)
    • 8.5.2 MultiStem (Athersys): Fails Phase II Ulcerative Colitis, Still Undergoing Phase I as Immunomodulation Therapy after Liver Transplantation
    • 8.5.3 BioTime: Multiple Subsidiaries Focused on Regenerative Medicine
      • 8.5.3.1 AST-OPC1 and AST-VAC2 (Asterias Biotherapeutics)
      • 8.5.3.2 OpRegen (Cell Cure Neurosciences)
      • 8.5.3.3 Other BioTime Subsidiaries Related to Stem Cells: OncoCyte, ReCyte, ESI Bio, LifeMap Sciences Etc.
    • 8.5.4 Calimmune: Dual Anti-HIV Gene Therapy via Stem Cells
    • 8.5.5 (PDA-001 and PDA-002) Celgene Corporation
    • 8.5.6 ReJoin (Cellular Biomedicine Group): Interim Results from the MSCs for Knee Osteoarthritis
    • 8.5.7 PNEUMOSTEM (MEDIPOST)
      • 8.5.7.1 NEUROSTEM (MEDIPOST): Undergoing Phase I/II Trial and Obtains Patents around the Globe
    • 8.5.8 Translational Biosciences: Set Up for the Sole Purpose of Conduction Stem Cell Clinical Trials, Five Phase I/II Trials Ongoing
    • 8.5.9 Mesoblast: MPCs for Various Indications
      • 8.5.9.1 MPC-300-IV in Diabetes
      • 8.5.9.2 MPC-300-IV in Rheumatoid Arthritis
      • 8.5.9.3 MPC-06-ID in Chronic Back Pain, Enters Phase III
    • 8.5.10 Pluristem Therapeutics: Uses PLX Cells to Secrete Therapeutic Proteins in Damaged Tissues
      • 8.5.10.1 PLX-PAD: Phase II for Intermittent Claudication
      • 8.5.10.2 PLX-PAD: Completes Phase I/II for Injured Gluteal Muscle
      • 8.5.10.3 PLX-R18: In Preclinical Development for ARS
    • 8.5.11 Regeneus: Adipose Derived MSC Therapies
      • 8.5.11.1 Progenza Undergoing Phase I Trial
    • 8.5.12 S-Evans Biosciences: Menstrual Stem Cells
    • 8.5.13 TiGenix: Expanded Adipose-Derived Stem Cell Therapies
      • 8.5.13.1 EASC Technology Platform
      • 8.5.13.2 Cx601: Meets Primary Endpoint in Phase 3 Trial
      • 8.5.13.4 Cx611 for Rheumatoid Arthritis and also Severe Sepsis
      • 8.5.13.5 Cx621 - Positive Results from Phase I Trial, but Development on Hold
      • 8.5.13.6 ChondroCelect Already on the Market - Although is More of a Cell Therapy Rather than a Stem Cell Therapy
    • 8.5.14 VC-01 (ViaCyte)
  • 8.6 Genetically Modified Stem Cell Therapies
    • 8.6.1 BluebirdBio: Gene-Modified HSCs for Orphan Diseases
    • 8.6.2 GSK: Stem Cell Gene Therapies for Rare Diseases, including one which has been Submitted for Approval in Europe

9. Stem Cell Non-Therapeutic Applications 2019-2030

  • 9.1 Stem Cell Non-Therapeutic Applications: Overview and Current Status
  • 9.2 Stem Cell Non-Therapeutic Applications: Market Forecast 2019-2030
  • 9.3 Stem Cell Banking: Growing Demand Worldwide
    • 9.3.1 Impact of the current epidemic of Zika Virus and HIV in cord cell banking
    • 9.3.2 Is there a Need for Stem Cell Banking as a Form of 'Health Insurance'?
    • 9.3.3 Stem Cell Banking Companies in the US and Around the World
    • 9.3.4 Dental Stem Cell Banking: An Alternative to Cord Blood Banks?
  • 9.4 Stem Cell Supply and Processing: iPSCs are the New Driver
    • 9.4.1 Stem Cell Supply and Processing Companies
  • 9.5 Stem Cell-Based Assays: Major Potential for Preclinical Screens
    • 9.5.1 Advantages of Stem Cell-Based Assays
    • 9.5.2 Stem Cell-Based Assay Companies
  • 9.6 Research, Reagents, and Other Non-Therapeutic Stem Cell Activities
  • 9.7 Drivers and Restraints

10. Qualitative Analysis of the Stem Cell Technologies and Applications Market 2019-2030

  • 10.1 SWOT Analysis of the Stem Cell Technologies and Applications Market
  • 10.2 Strengths
    • 10.2.1 HSCT is already an Established Procedure
    • 10.2.2 Approvals for Stem Cell Therapies
    • 10.2.3 Relaxation of Regulatory Barriers
  • 10.3 Weaknesses
    • 10.3.1 Phase III Trials only make up a Small Fraction of the Currently Ongoing Clinical Trials
    • 10.3.2 Uncertain Mechanisms of Action in Stem Cell Therapies
    • 10.3.3 Regulatory and Reimbursement Concerns
    • 10.3.4 The scare of a possible immune rejection after a stem cell transplant
  • 10.4 Opportunities
    • 10.4.1 Huge Potential in Unmet Clinical Needs
    • 10.4.2 Opportunities in the Non-Therapeutic Uses of Stem Cells, including Cord Blood Banking and Cell-Based Assays
    • 10.4.3 Interactions with Related Technologies will Offer new Opportunities
    • 10.4.4 Genetic Modification of Stem Cells
  • 10.5 Threats
    • 10.5.1 Financial Risks and Under-Capitalisation of the Stem Cells Sector
    • 10.5.2 Threat of Pipeline Failures
    • 10.5.3 Long-Term Safety Concerns
  • 10.6 STEP Analysis of the Stem Cell Technologies and Applications Market
  • 10.7 Social Factors
    • 10.7.1 Increasing Burden of Disease as World Population Ages
    • 10.7.2 Biological Insurance through Stem Cell Banking
    • 10.7.3 Stem Cell Tourism: Both an Opportunity and Threat to the Market
  • 10.8 Technological Factors
    • 10.8.1 Increasing Research Output
    • 10.8.2 IPSC Advances
    • 10.8.3 Greater Understanding of Stem Cell Differentiation
    • 10.8.4 Interactions with Other Technologies
    • 10.8.5 CRISPR: A Breakthrough in Genome Editing
  • 10.9 Economic Factors
    • 10.9.1 Grey Market for Stem Cell Therapies
    • 10.9.2 Broad Changes in Pharma / Healthcare Markets
    • 10.9.3 New Business Models are required due to the Unique Challenges Posed by these Non- Traditional Therapies
  • 10.10 Political Factors
    • 10.10.1 Controversies over Embryonic Stem Cell Research
    • 10.10.2 Support from National Governments
    • 10.10.3 Patient Pressure to Deregulate the Stem Cell Therapies Market

11. Company Profiling

  • 11.1 Lineage Cell Therapeutics, Inc.
  • 11.2 Osiris Therapeutics, Inc.
  • 11.3 Brainstorm Cell Therapeutics Inc.
  • 11.4 Celgene corporation, a Bristol-Myers Squibb Company
  • 11.5 Cynata Therapeutics
  • 11.6 Vericel Corporation
  • 11.7 Athersys, Inc.
  • 11.8 Cytori Therapeutics Inc.
  • 11.9 Seneca Biopharmaceuticals, Inc.
  • 11.10 Caladrius Biosciences
  • 11.11 Sangamo Therapeutics
  • 11.12 Gamida Cell
  • 11.13 Cellular Biomedicine Group
  • 11.14 Pluristem Therapeutics, Inc.
  • 11.15 VistaGen Therapeutics, Inc.

12. Conclusions

  • 12.1 Stem Cell Technologies and Applications: An Emerging Market
  • 12.2 Current Leading Segments and Regional Markets
  • 12.3 World Stem cell Technologies and Applications Market Forecast 2019-2030
  • 12.4 The Future of Stem Cell Market
  • 12.5 Concluding Remarks
    • Glossary
    • Associated Reports
    • Visiongain Report Sales Order
    • About Visiongain
    • Visiongain report evaluation form

List of Tables

  • Table 2.1 Classifying Stem Cells by Potency
  • Table 2.2 The Different Germ Layers and Their Associated Types of Cells and Organs
  • Table 2.3 Main Types of Stem Cells and Their Properties
  • Table 2.4 Stem Cell Donor Terminology
  • Table 2.5 Different Phases of Clinical Trials
  • Table 3.1 NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2016 2017, and January 2020
  • Table 3.2 Estimated and expected NIH spending in Stem cell research from 2015-2020 (expected) (in million USD)
  • Table 3.3 CIRM Industry Support 2018
  • Table 3.3 New FDA Draft Guidance's
  • Table 3.5 StemGen's Classifications of European Nations by Level of Permissiveness towards hESC research
  • Table 4.1 Stem Cell Technologies and Applications Market by Region: Revenues ($m), Market Shares (%), 2018
  • Table 4.2 North America Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 4.3 North America Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 4.4 Europe Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 4.5 Europe Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 4.6 Asia Pacific Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 4.7 Asia Pacific Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 4.8 Rest of the World Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 4.9 Rest of the World Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 4.10 Stem Cell Technologies and Applications Market by Segment: Revenues ($m), Market Shares (%), 2019
  • Table 4.11 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2020-2024
  • Table 4.12 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 5.1 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 5.2 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 5.3 Comparison of Bone Marrow, Peripheral Blood and Cord Blood for HSCT
  • Table 5.4 Estimated Number of HSCT Operations Performed Globally, by Donor Type: AGR (%), CAGR (%), 2015-2017
  • Table 5.5 European HSCT Operations: Number of Operations by Donor Type, 2011-2017
  • Table 5.6 Indications with Medicare Coverage for HSCT (both Autologous and Allogeneic)
  • Table 5.7 Malignancies and Other Haematological Diseases which may be Treated with HSCT
  • Table 5.8 HSCT-Addressable Cancers: Estimated Combined Incidence in the US, Japan and Western Europe (Number of Cases), CAGR (%), 2012-2024
  • Table 5.9 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2018
  • Table 5.10 Past and Present ProHema (Fate Therapeutics) Clinical Trials
  • Table 5.11 MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 5.12 MSC-100-IV/Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 5.13 HSC835 (Novartis) Ongoing Clinical Trials, 2017
  • Table 6.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 6.2 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 6.3 Global Cardiovascular Disease Market by Drug Class: Revenue($bn), 2018
  • Table 6.4 Hearticellgram-AMI (Pharmicell) Sales Estimates: Revenue ($m), AGR (%), 2014-2017
  • Table 6.5 Hearticellgram-AMI Forecast (Pharmicell): Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 6.6 Hearticellgram-AMI Forecast (Pharmicell): Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 6.7 CardioRel (Reliance Life Sciences) Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 6.8 CardioRel (Reliance Life Sciences) Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 6.9 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
  • Table 6.10 Advantages and disadvantages of different clinical trials that are ongoing
  • Table 6.11 Past and Present MultiStem (Athersys) Clinical Trials, 2018
  • Table 7.1 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 7.2 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 7.3 Ongoing MA09-hRPE (Ocata Therapeutics) Clinical Trials in SMD, 2018
  • Table 7.4 Ongoing MA09-hRPE (Ocata Therapeutics) Clinical Trials in AMD
  • Table 8.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 8.2 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 8.3 Osteocel Plus Forecast (NuVasive): Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 8.4 Osteocel Plus Forecast (NuVasive): Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 8.5 Trinity Evolution and Elite (Orthofix): Revenues ($m), AGR (%), CAGR (%), 2010-2014
  • Table 8.6 Trinity Evolution and Elite (Orthofix) Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 8.7 Trinity Evolution and Elite (Orthofix) Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 8.8 CARTISTEM Revenues: Revenue ($m), AGR (%), 2014-2016
  • Table 8.9 CARTISTEM (MEDIPOST) Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024 2025
  • Table 8.10 CARTISTEM (MEDIPOST) Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2029 2030
  • Table 8.11 Non-Oncologic Diseases which can be Treated with HSCT
  • Table 8.12 Processes and Mechanisms of Bone Repair
  • Table 8.13 Anterogen Clinical Trials, 2018
  • Table 8.14 PDA-002 (Celgene Corporation) Current Clinical Trials
  • Table 8.15 PNEUMOSTEM (MEDIPOST) Past and Present Clinical Trials
  • Table 8.16 Translational Biosciences Currently Open Clinical Trials, 2015
  • Table 8.17 S-Evans Biosciences Clinical Trials, 2015
  • Table 9.1 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 9.2 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2025-2030
  • Table 9.3 Selected US Stem Cell Banks, 2018
  • Table 9.4 Selected Non-US Stem Cell Banks, 2017
  • Table 9.5. Prominent Dental Stem Cell Banks Globally
  • Table 9.6 Selected Stem Cell Supply and Processing Companies
  • Table 9.7 Selected Companies with Involvement in Stem Cell-Based Assays, 2017
  • Table 10.1 World 65+ Population Forecast: Population (m), 2015-2050
  • Table 11.1 Lineage Cell Therapeutics, Inc.: Overview
  • Table 11.2 Osiris Therapeutics, Inc.: Overview
  • Table 11.3 BRAINSTORM CELL THERAPEUTICS INC.: Overview
  • Table 11.4 Celgene Corporation: Overview
  • Table 11.5 Cynata Therapeutics: Overview
  • Table 11.6 Vericel Corporation: Overvie
  • Table 11.7 Athersys, Inc.: Overview
  • Table 11.8 Athersys, Inc.: Clinical Pipeline.
  • Table 11.9 Cytori Therapeutics Inc.: Overview
  • Table 11.10 Seneca Biopharmaceuticals, Inc.: Overview
  • Table 11.11 Caladrius Biosciences: Overview
  • Table 11.12 Sangamo Therapeutics: Overview
  • Table 11.13 Gamida Cell: Overview
  • Table 11.14 Gamida Cell: Clinical Pipeline
  • Table 11.15 Cellular Biomedicine Group: Overview
  • Table 11.16 Cellular Biomedicine Group: Clinical Pipeline
  • Table 11.17 Pluristem: Overview
  • Table 11.18 Pluristem: Clinical Pipeline PLX-R18
  • Table 11.19 VistaGen Therapeutics, Inc.: Overview

List of Figures

  • Figure 1.1 Global Stem Cell Technologies and Applications Market Segmentation Overview, 2019
  • Figure 2.1 Timeline of Stem Cell Research
  • Figure 3.1 NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2017
  • Figure 3.2 NIH Spending for stem cell research by year (in USD billions)
  • Figure 3.3 CIRM Funding by Disease Area, Percentage (%), 2018
  • Figure 4.1 Therapeutic Applications of Stem Cells vs Non-Therapeutic Applications: Market Shares (%), 2019
  • Figure 4.2 Therapeutic Applications of Stem Cells vs Non-Therapeutic Applications: Market Shares (%), 2030
  • Figure 4.3 Stem Cell Technologies and Applications Market by Region: Market Shares (%), 2019
  • Figure 4.4 Stem Cell Technologies and Applications Market by Region: Market Shares (%), 2030
  • Figure 4.6 Stem Cell Technologies and Applications Market by Region: Market Shares (%), 2019- 2030
  • Figure 4.7 North America Stem Cell Technologies and Applications Market Forecast: Therapeutics Revenues ($m), 2019-2030
  • Figure 4.8 North America Stem Cell Technologies and Applications Market Forecast: Cancer Therapeutics Revenues ($m), 2019-2030
  • Figure 4.9 North America Stem Cell Technologies and Applications Market Forecast: Cardiovascular Therapeutics Revenues ($m), 2019-2030
  • Figure 4.10 North America Stem Cell Technologies and Applications Market Forecast: CNS Therapeutics Revenues ($m), 2019-2030
  • Figure 4.11 North America Stem Cell Technologies and Applications Market Forecast: Other Therapeutics Revenues ($m), 2019-2030
  • Figure 4.12 North America Stem Cell Technologies and Applications Market Forecast: Non- Therapeutics Revenues ($m), 2019-2030
  • Figure 4.13 Europe Stem Cell Technologies and Applications Market Forecast: Therapeutics Revenues ($m), 2019-2030
  • Figure 4.14 Europe Stem Cell Technologies and Applications Market Forecast: Cancer Therapeutics Revenues ($m), 2019-2030
  • Figure 4.15 Europe Stem Cell Technologies and Applications Market Forecast: Cardiovascular Therapeutics Revenues ($m), 2019-2030
  • Figure 4.16 Europe Stem Cell Technologies and Applications Market Forecast: CNS Therapeutics Revenues ($m), 2019-2030
  • Figure 4.17 Europe Stem Cell Technologies and Applications Market Forecast: Other Therapeutics Revenues ($m), 2019-2030
  • Figure 4.18 Europe Stem Cell Technologies and Applications Market Forecast: Non-Therapeutics Revenues ($m), 2019-2030
  • Figure 4.19 Asia Pacific Stem Cell Technologies and Applications Market Forecast: Therapeutics Revenues ($m), 2019-2030
  • Figure 4.20 Asia Pacific Stem Cell Technologies and Applications Market Forecast: Cancer Therapeutics Revenues ($m), 2019-2030
  • Figure 4.21 Asia Pacific Stem Cell Technologies and Applications Market Forecast: Cardiovascular Therapeutics Revenues ($m), 2019-2030
  • Figure 4.22 Asia Pacific Stem Cell Technologies and Applications Market Forecast: CNS Therapeutics Revenues ($m), 2019-2030
  • Figure 4.23 Asia Pacific Stem Cell Technologies and Applications Market Forecast: Other Therapeutics Revenues ($m), 2019-2030
  • Figure 4.24 Asia Pacific Stem Cell Technologies and Applications Market Forecast: Non- Therapeutic Revenues ($m), 2019-2030
  • Figure 4.25 Rest of the World Stem Cell Technologies and Applications Market Forecast: Therapeutics Revenues ($m), 2019-2030
  • Figure 4.26 Rest of the World Stem Cell Technologies and Applications Market Forecast: Cancer Therapeutics Revenues ($m), 2019-2030
  • Figure 4.27 Rest of the World Stem Cell Technologies and Applications Market Forecast: Cardiovascular Therapeutics Revenues ($m), 2019-2030
  • Figure 4.28 Rest of the World Stem Cell Technologies and Applications Market Forecast: CNS Therapeutics Revenues ($m), 2019-2030
  • Figure 4.29 Rest of the World Stem Cell Technologies and Applications Market Forecast: Other Therapeutics Revenues ($m), 2019-2030
  • Figure 4.30 Rest of the World Stem Cell Technologies and Applications Market Forecast: Non- Therapeutics Revenues ($m), 2019-2030
  • Figure 4.31 Stem Cell Technologies and Applications Market by Therapeutics: Market Shares (%), 2019
  • Figure 4.32 Stem Cell Technologies and Applications Market by Therapeutics: Market Shares (%), 2030
  • Figure 4.33 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), 2019- 2030
  • Figure 4.34 Stem Cell Technologies and Applications Market Forecast by Segment: Revenue ($m), 2019-2030
  • Figure 4.35 Stem Cell Technologies and Applications Market: Market Shares (%) by Segment, 2025
  • Figure 4.36 Stem Cell Technologies and Applications Market: Market Shares (%) by Segment, 2030
  • Figure 4.37 Stem Cell Technologies and Applications Market: Market Shares (%) by Cancer Therapeutics, 2019-2030
  • Figure 4.38 Stem Cell Technologies and Applications Market: Market Shares (%) by Cardiovascular Therapeutics, 2019-2030
  • Figure 4.39 Stem Cell Technologies and Applications Market: Market Shares (%) by CNS Therapeutics, 2019-2030
  • Figure 4.40 Stem Cell Technologies and Applications Market: Market Shares (%) by Other Therapeutics, 2019-2030
  • Figure 4.41 Stem Cell Technologies and Applications Market: Market Shares (%) by Therapeutics, 2019-2030
  • Figure 4.42 Stem Cell Technologies and Applications Market: Market Shares (%) by Non- Therapeutics, 2019-2030
  • Figure 4.43 Stem Cell Technologies and Applications Market: Market Shares (%) by Application, 2019-2030
  • Figure 5.1 Estimated Proportions of Global HSCT Operations by Donor Type, 2017
  • Figure 5.2 European HSCT Operations by Donor Type, 2011-2017
  • Figure 5.3 Estimated New Cases of Leukaemia, Lymphoma and Myeloma in 2017
  • Figure 5.4 Estimated new cases of leukaemia diagnosed in 2017
  • Figure 5.5 HSCT-Addressable Cancers: Estimated Combined Incidence in the US, Japan and Western Europe (Number of Cases), 2012-2024
  • Figure 5.6 Most Common Diseases Treated by Cord Blood from LifeCord: Percentage (%) 2017
  • Figure 5.7 MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenue ($m), 2019-2030
  • Figure 5.8 Stem Cell Cancer Therapeutics Market: Drivers and Restraints
  • Figure 6.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenue ($m), 2019-2030
  • Figure 6.2 Global Cardiovascular Disease Market by Drug Class: Market Shares (%), 2018
  • Figure 6.3 Hearticellgram-AMI (Pharmicell) Sales Estimates: Revenue ($m), 2014-2017
  • Figure 6.5 CardioRel (Reliance Life Sciences) Forecast: Revenue ($m), 2019-2030
  • Figure 6.6 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), 2015 and 2030
  • Figure 6.7 Stem Cell Cardiovascular Therapeutics Market: Drivers and Restraints, 2019-2030
  • Figure 7.1 Stem Cell CNS Therapeutics Market Forecast: Revenue ($m), 2019-2030
  • Figure 7.2 Stem Cell CNS Therapeutics Market: Drivers and Restraints
  • Figure 8.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m) 2019- 2030
  • Figure 8.2 Osteocel Plus (NuVasive) Forecast: Revenue ($m), 2019-2030
  • Figure 8.3 Trinity Evolution and Elite (Orthofix): Revenue ($m), 2010-2014
  • Figure 8.4 Trinity Evolution and Elite (Orthofix): Revenue ($m), 2019-2030
  • Figure 8.5 CARTISTEM (MEDIPOST) Forecast: Revenues ($m) 2019-2029 2030
  • Figure 9.1 Stem Cell Non-Therapeutic Applications Market Forecast: Revenue ($m), 2019-2030
  • Figure 9.2 Stem Cell Non-Therapeutic Applications Market: Drivers and Restraints
  • Figure 10.1 SWOT Analysis of the Stem Cell Technologies and Applications Market
  • Figure 10.2 STEP Analysis of the Stem Cell Technologies and Applications Market
  • Figure 10.3 World 65+ Population Forecast: Population (m), 2015-2050
  • Figure 12.1 Stem Cell Technologies and Applications Market Forecast, split by Therapeutic vs Non-Therapeutic Applications: Revenue ($m), 2019-2030

List of Companies and Organisations mentioned in the report:

  • AgeX Therapeutics
  • AllCells
  • AlloSource
  • Americord
  • Angiocrine Bioscience
  • Anterogen
  • Apceth
  • Arteriocyte
  • Astellas Pharma US, Inc.
  • Asterias Biotherapeutics, Inc.
  • Athersys, Inc.
  • Axiogenesis
  • Baxter Healthcare
  • BaYi Brain Hospital
  • BioCardia
  • BioE
  • BioEden
  • Biogenea-Cellgenea
  • Bioheart, Inc.
  • Biologic Therapies
  • BioMet Orthopedics
  • BioTime Asia
  • BioTime, Inc
  • Bloodworks
  • Bluebird Bio
  • Brainstorm Cell Therapeutics Inc.
  • Caladrius Biosciences
  • Calimmune
  • Caribou
  • Celgene Corporation
  • Cell Cure Neurosciences
  • Cell Targeting
  • Cellartis
  • Cellerant Therapeutics, Inc.
  • Cellular Dynamics
  • Cellular Biomedicine Group
  • Cellular Dynamics International
  • Cephalon
  • Cesca Therapeutics
  • Ceylad
  • China Cord Blood Corporation
  • Chugai Pharmaceutical Co. Ltd.
  • ClinImmune Labs
  • Cognate BioServices
  • Cook General
  • BioTechnology
  • Cord Blood America
  • Cord Blood Registry Systems
  • Cordlife Group
  • CordVida
  • CRISPR Therapeutics
  • Cryo-Cell
  • International
  • CryoCord
  • CryoHaldco
  • Cryo-Save
  • CryoViva
  • CXR Biosciences
  • Cynata Therapeutics Ltd.
  • Cytori Therapeutics, Inc.
  • Dong-A Pharmaceuticals Co.
  • ESI BIO
  • Evotec
  • Fate Therapeutics, Inc.
  • FDS Pharma
  • Fondazione Centro San Raffaele
  • Fondazione Telethon
  • Forty Seven, Inc.
  • Fresenius
  • FUJIFILM Co., Ltd.
  • Gamida Cell Ltd.
  • Geron Corporation
  • GlaxoSmithKline
  • HSCI
  • Humacyte, Inc
  • Human Stem Cells Institute
  • Innovative Cellular Therapeutics
  • Insception Biosciences
  • Intellia Therapeutics
  • IntelliCell Biosciences
  • International Stemcell Services
  • JCR Pharmaceuticals
  • Johnson & Johnson
  • Lifebank Cryogenics
  • LifebankUSA
  • Lineage Cell Therapeutics, Inc.
  • Maxcyte
  • MedCell Bioscience
  • MEDIPOST
  • Medtronic
  • Mesoblast
  • Miltenyi Biotec
  • National Dental Pulp Laboratory
  • Neurolastem
  • New England Cord Blood Bank
  • Nohla Therapeutics
  • Novartis
  • NuVasive
  • Ocata Therapeutics
  • Omidubicel
  • Opexa Therapeutics
  • Orchard Therapeutics
  • Orthofix
  • Osiris
  • Osiris Therapeutics
  • Pharmicell
  • Pharmsynthez
  • Plasticell
  • Pluristem Therapeutics Inc.
  • Poseida Therapeutics, Inc.
  • Quest Biomedical
  • QYuns Therapeutics
  • ReCyte Therapeutics
  • Regenerex
  • Regeneus
  • Reliance Life Sciences'
  • ReNeuron
  • ReNeuron
  • ReproCELL
  • RIKEN
  • Roche
  • Roslin Cellab
  • RTI Biologics
  • RUSNANO
  • SanBio
  • Sangamo Therapeutics, Inc.
  • Seneca Biopharma, Inc.
  • S-Evans Biosciences
  • Sorrento Therapeutics Inc.
  • Spinesmith Partners
  • St. Jude's
  • Stemcell Technologies
  • StemCells
  • StemCore
  • StemCyte
  • StemImmune Inc.
  • SwissMedic
  • Tigenix
  • TransCell
  • U.S. Stem Cell, Inc.
  • United Therapeutics Corp
  • Vericel Corporation
  • ViaCord
  • ViaCyte, Inc.
  • VistaGen Therapeutics, Inc.
  • Vita34
  • W.L. Gore & Associates, Inc.

List of Universities and Organisations

  • American Academy of Pediatrics
  • American Society of Clinical Oncology
  • California Institute for Regenerative Medicine
  • Cedars-Sinai Heart Institute
  • Duke University School of Medicine
  • LifeSouth Community Blood Centers
  • Mayo Clinic
  • Seoul National University
  • SSM Cardinal Glennon Children's Medical Center
  • University of Colorado
  • University of Minnesota
  • University of Wisconsin
Back to Top